Suppressive activity of fexofenadine hydrochloride on nitric oxide production in-vitro and in-vivo

Journal of Pharmacy and Pharmacology

Volumn 59, Issue 10, 2007, Pages 1389-1395

  Asano, Kazuhito ^a   Kanai, Ken Ichi ^a   Furuta, Atsuko ^a   Furuya, Ayako ^a   Suzaki, Harumi ^a   Hisamitsu, Tadashi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; CELL CULTURE; CELL STIMULATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NOSE; PROTEIN EXPRESSION; SUPERNATANT; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GENE EXPRESSION REGULATION; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HYPERSENSITIVITY; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; NASAL POLYPS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; TERFENADINE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35349030939     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.59.10.0009     Document Type: Article

References (42)

1. Abdel-Raheem, I. T., Hide, I., Yanase, Y., Shigemoto-Mogami, Y., Sakai, N., Shirai, Y., Saito, N., Hamada, F. M., El-Mahdy, N. A., Elsisy, A. D., Sokar, S. S., Nakata, Y. (2005) Protein kinase C alpha mediates TNF release process in RBL-2H3 mast cells. Br. J. Pharmacol. 145: 415-423
2. Asano, K., Kanai, K., Suzaki, H. (2004a) Suppressive activity of fexofenadine hydrochloride on thymus-activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro. Int. Arch. Allergy Immunol. 133: 267-275
3. Asano, K., Kanai, K., Suzaki, H. (2004b) Suppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitro. Clin. Exp. Allergy 34: 1890-1898
4. Asano, K., Kanai, K., Suzaki, H. (2004c) Suppressive activity of fexofenadine hydrochloride on the production of eosinophil chemoattractants from human nasal fibroblasts in vitro. Arzneimittelforschung 54: 436-443
5. Barnes, P. J. (1990) Reactive oxygen species and airway inflammation. Free Radic. Biol. Med. 9: 235-243
6. Bentley, A. M., Jacobson, M. R., Cumberworth, V., Barkans, J. R., Moqbel, R., Schwartz, L. B., Irani, A. M., Kay, A. B., Durham, S. R. (1992) Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increased in activated eosinophils and epithelial mast cells. J. Allergy Clin. Immunol. 89: 877-883
7. Beutler, B. A., Milsark, I. W., Cerami, A. (1985) Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J. Immunol. 135: 3972-3977
8. Bisgaard, H., Loland, L., Anhoj, J. (1999) NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am. J. Respir. Crit. Care Med. 160: 1227-1231
9. Bousquet, J., Chanez, P., Campbell, A. M., Vignola, A. M., Godard, P. (1995) Cellular inflammation in asthma. Clin. Exp. Allergy 2: 39-42
10. Casale, T. B., Andrade, C., Qu, R. (1999) Safety and efficacy of once-daily fexofenadine-HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc. 20: 193-198
11. Chan, E. D., Riches, D. W. H. (1998) Potential role of the JNK/SAPK signal transduction pathway in the induction of iNOS by TNF-α. Biochem. Biophys. Res. Comm. 253: 790-796
12. Cuzzocre, S. (2001) Role of nitric oxide and reactive oxygen species in arthritis. In: Salvemini D, Billiar TR, Vodovotz Y (eds) Nitric oxide and inflammation. Birkhauser Verlag, Basel, pp 145-160
13. Ferdinandy, P., Schulz, R. (2001) Roles of nitric oxide, superoxide, and peroxinitrite in myocardiac ischemic-reperfusion injury and ischemic preconditioning. In: Salvemini D, Billiar TR, Vodovotz Y (eds) Nitric oxide and inflammation. Birkhauser Verlag, Basel, pp 191-206
14. Gaston, B., Drazen, J. M., Loscalzo, J., Stampler, J. S. (1994) The biology of nitrogen oxides in the airways. Am. J. Respir. Crit. Care Med. 149: 538-551
15. Gratziou, G. Rovina, N., Lignos, M., Vogiatzis, I., Roussos, C. H. (2001) Exhaled nitric oxide in seasonal allergic rhinitis: influence of pollen season and therapy. Clin. Exp. Allergy 31: 409-416
16. Harbrecht, B. G., Di Silvio, M., Demetris, A. J., Simmons, R. L., Billiar, T. R. (1994) Tumor necrosis factor-alpha regulates in vivo nitric oxide synthesis and induces liver injury during endotoxemia. Hepatology 20: 1055-1060
17. Harbrecht, B. G., Taylor, B. S., Xu, Z., Ramalakslumi, S., Ganster, R. W., Geller, D. A. (2001) cAMP inhibits inducible nitric oxide synthase expression and NF-κB-binding activity in cultured rat hepatocytes. J. Surg. Res. 99: 258-264
18. Hirano, S., Asano, K., Namba, M., Kanai, K., Hisamitsu, T., Suzaki, H. (2003) Induction of apoptosis in nasal fibroblasts by glucocorticoids in vitro. Acta Otolaryngol. 123: 1075-1079
19. Howarth, P. H. (1989) Allergic rhinitis: a rational choice of treatment. Respir. Med. 83: 179-188
20. Kang, K. W., Wagley, Y., Kim, H. W., Pokharel, Y. R., Chung, Y. Y., Chang, I. Y., Kim, J. J., Moon, J. S., Kim, Y. K., Nah, S. Y., Kang, H. S., Oh, J. W. (2007) Novel role of IL-6/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10. 9 cells. Free Radic. Biol. Med. 42: 215-227
21. Kleinert, H., Schwarz, P. M., Forstermann, U. (2003) Regulation of the expression of inducible nitric oxide synthase. Biol. Chem. 384: 1343-1364
22. Kooy, N. W., Royall, J. A., Ye, Y. Z., Kelly, D. R., Beckman, J. S. (1995) Evidence for in vivo peroxynitrite production in human acute lung injury. Am. J. Respir. Crit. Care Med. 151: 1250-1254
23. Kristof, A. S., Fielhaber, J., Triantafillopoulos, A., Nemoto, S., Moss, J. (2005) Phosphatidylinositol 3-kinase-dependent suppression of the human inducible nitric-oxide synthase promoter mediated by FKHRL1. J. Biol. Chem. 28: 23958-23968
24. Markham, A., Wagstaff, A. J. (1998) Fexofenadine. Drugs 55: 269-274
25. Martin, U., Bryden, K., Devoy, M., Howarth, P. (1996) Allergens, IgE, mediators, inflammatory mechanisms: increased levels of exhaled nitric oxide during nasal and oral breathing in subjects with seasonal rhinitis. J. Allergy Clin. Immunol. 97: 768-772
26. Moores, S. L., Schanber, M. D., Mosser, S. D., Rands, E., O'Hara, M. B., Garsky, V. M., Marshall, M. S., Pompliano, D. L., Gibbs, J. B. (1991) Sequence dependence of protein isoprenylation. J. Biol. Chem. 266: 14603-14610
27. Na, H. J., Lee, S. J., Kang, Y. G. Cho, Y. L., Nam, W. D., Kim, P. K., Ha, K. S., Chung, H. T., Lee, H., Kwon, Y. G. (2004) Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation. J. Immunol. 173: 1276-1283
28. Pang, L., Hoult, J. R. (1997) Repression of inducible nitric oxide synthase and cyclooxygenase-2 by prostaglandin E2 and other cyclic AMP stimulations in J774 macrophages. Biochem. Pharmacol. 53: 493-500
29. Pietersz, G. A., Toohey, B., Mckenzie, I. F. (1998) In vitro and in vivo evaluation of human tumor necrosis factor-alpha (hTNFalpha) chemically conjugated to monoclonal antibody. J. Drug Target 5: 109-120
30. Redington, A. E. (2006) Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. Eur. J. Pharmacol. 533: 263-276
31. Reiss, Y., Stradley, S. J., Gierasch, L. M., Brown, M. S., Goldstein, J. L. (1991) Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc Natl Acad Sci USA 88: 732-736
32. Robinson, E. K., Seaworth, C. M., Suliburk, J. W., Adams, S. D., Kao, L. S., Mercer, D. W. (2006) Effect of NOS inhibition on rat gastric matrix metalloproteinase production during endotoxemia. Shock 25: 507-514
33. Sannohe, S., Adach, T., Hamada, K., Honda, K., Yamada, Y., Saito, N., Cui, C. H., Kayaba, H., Ishikawa, K., Chihara, J. (2003) Upregulated response to chemokines in oxidative metabolism of eosinophils in asthma and allergic rhinitis. Eur. Respir. J. 21: 925-931
34. Silkoff, P. E., Romero, F. A., Gupta, N., Townley, R. G., Milgrom, H. (2004) Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics 113: 308-312
35. 1-receptor antagonists. J. Allergy Clin. Immunol. 107: 526-530
36. St Denis, A., Chano, F., Tremblay, P., St-Pierre, Y., Descoteaux, A. (1998) Protein kinase C-Q modulates lipopolysaccharide-induced functions in a murine macrophage cell line. J. Biol. Chem. 273: 32787-32792
37. Taylor, B. S., Geller, D. A. (2001) Regulation of the inducible nitric oxide synthase (iNOS) gene. In: Salvemini D. Billiar TR, Vodovotz Y (eds) Nitric oxide and inflammation. Birkhauser Verlag, Basel, pp 1-27
38. Terao, H., Asano, K., Kanai, K., Kyo, Y., Watanabe, S., Hisamitsu, T., Suzaki, H. (2003) Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. Med. Inflamm. 12: 195-202
39. Wadsworth, T. L., Koop, D. R. (2001) Effect of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced release of nitric oxide. Chem. Biol. Interact. 137: 43-58
40. Xia, Y., Zweier, J. L. (2001) Superoxide anion release from inducible nitric oxide. In: Salvemini D, Billiar TR, Vodovotz Y (eds) Nitric oxide and inflammation. Birkhauser Verlag, Basel, pp 27-39
41. Xue, X., Kuei-Tai, A. L., Huang, J. F., Gu, Y., Karlsson, L., Fourie, A. (2006) Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib. J. Pharmacol. Exp. Ther. 317: 53-60
42. Yermilov, V., Rubio, J., Ohshima, H. (1995) Formation of 8-nitroguanidine in DNA treated with peroxynitrite in vitro and its rapid removal from DNA by depurination. FEBS Lett. 376: 207-210